
235 Participants screened
65 Low UACR
6 High serum potassium
2 Low blood pressure
17 Did not meet inclusion criterion
4 Allergic or intolerant to ACEi
11 Serious medical condition
2 Withdrew consent
128 entered Run-in phase
16 Low UACR
6 High serum potassium
3 Low blood pressure
4 Did not meet inclusion criterion
7 Serious medical condition
7 Withdrew consent
1 Lost to follow-up
2 Study closed prior to randomization
1 Non-compliance
81 Randomized
27 assigned to Placebo
27 assigned to Losartan
1 withdrew prior to first dose
27 assigned to Spironolactone
6 of 27 ITT withdrew
1 Withdrew consent
3 Lost to follow-up
1 Stroke
1 Increased serum creatinine
8 of 26 ITT withdrew
3 Withdrew consent
3 Lost to follow-up
1 Stroke
1 Death
10 of 27 ITT withdrew
2 Withdrew consent
1 Lost to follow-up
2 Hyperkalemia
2 Stroke
1 Hypotension
1 Increased serum creatinine
1 Gynecomastia
21 completed 48 weeks of treatment
21 completed 48 weeks of treatment
17 completed 48 weeks of treatment
1 Death
2 Lost to follow-up
21 completed 52 week washout
18 completed 52 week washout
17 completed 52 week washout